Evaluation of intrauterine insemination practices A 1 year prospective study in seven French assisted reproduction technology centers

Wednesday, June 1, 2016
Gonadotropin-releasing hormone antagonist used with multifollicular stimulation allows high delivery rates in intrauterine insemination.

Read More

Age independent from ovarian reserve status is the main prognostic factor in natural cycle in vitro fertilization

Tuesday, April 5, 2016

Authors:
Iñaki González-Foruria, M.D., Juana Peñarrubia, M.D., Aina Borràs, M.D., Dolors Manau, M.D., Gemma Casals, M.D., Sara Peralta, M.D., Montserrat Creus, M.D., Janisse Ferreri, M.D., Ester Vidal, Ph.D., Francisco Carmona, M.D., Juan Balasch, M.D., Francisco Fàbregues, M.D.…

Read More

Efficacy and safety of frozen thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial

Tuesday, March 29, 2016

Authors:
Robert Boostanfar, M.D., Davis Gates, Ph.D., Yanfen Guan, M.S., Keith Gordon, Ph.D., Christine McCrary Sisk, B.S., Barbara J.…

Read More

Antimullerian hormone: prediction of cumulative live birth in gonadotropin releasing hormone antagonist treatment for in vitro fertilization

Tuesday, September 29, 2015
Although antimullerian hormone added some value to predicting cumulative live birth rate, its predictive accuracy was only modest.

Read More

Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin releasing hormone antagonist protocol

Tuesday, September 29, 2015
The considerable variability in individual ovarian responses observed between repeated IVF cycles conducted using the same protocol were not explained by baseline serum follicle-stimulating hormone concentrations or antral follicle count.

Read More

Large comparative randomized double blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle stimulating hormone in a gonadotropin releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization

Monday, June 29, 2015
A single injection of corifollitropin alfa for the first 7 days of controlled ovarian stimulation was as effective as daily recombinant FSH in older IVF patients, and was generally well tolerated.

Read More

Gonadotropin releasing hormone agonist triggering of final follicular maturation for in vitro fertilization

Monday, March 30, 2015
These Views and Reviews articles examine the advantages and disadvantages of gonadotropin releasing hormone (GnRH) agonist for triggering the final stage of follicular maturation in in vitro fertilization (IVF).

Read More

Elevated early follicular progesterone levels and in vitro fertilization outcomes A prospective intervention study and meta analysis

Wednesday, July 30, 2014
Elevated progesterone levels on cycle day 2 affect ongoing pregnancy rates in gonadotropin-releasing hormone antagonist cycles.

Read More

Diminished ovarian reserve is the predominant risk factor for gonadotropin releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles

Wednesday, June 25, 2014
Patients who fail to remain suppressed in response to GnRH antagonists have significantly poorer ovarian reserve compared with patients who do not experience breakthrough LH surges.

Read More

Severe ovarian hyperstimulation syndrome following gonadotropin releasing hormone agonist trigger and freeze all approach in GnRH antagonist protocol

Monday, March 31, 2014
Two case reports are presented, in which GnRH triggering and the freeze-all approach in a GnRH antagonist protocol resulted in the development of severe OHSS, requiring hospitalization and peritoneal drainage.

Read More

Reference range for the antimullerian hormone Generation II assay A population study of 10984 women with comparison to the established Diagnostics Systems Laboratory nomogram

Friday, January 31, 2014
Antimüllerian hormone (AMH) exhibits an age-related decline, but the population distribution suggests that the current AMH Generation II assay standardization is not as reported by the manufacturer.

Read More

Measurement of antimüllerian hormone not as straightforward as it seems

Friday, January 31, 2014
Reflections on "Reference range for the antimüllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram" by Nelson et al.

Read More

Progesterone elevation does not compromise pregnancy rates in high responders a pooled analysis of in vitro fertilization patients treated with recombinant FSH GnRH antagonist in six trials

Wednesday, November 27, 2013
Incidence of elevated P increases with ovarian response, and elevated P (>1.5 ng/mL) is independently associated with a decreased chance of pregnancy in low to normal, but not high, responders.

Read More

The effectiveness of GnRH antagonist in poor ovarian responders undergoing in vitro fertilization a systematic review and meta analysis

Wednesday, November 27, 2013
In poor responders undergoing in vitro fertilization, the clinical efficacy of a gonadotropin-releasing hormone (GnRH) antagonist was similar to that of a GnRH agonist.

Read More

Dual trigger with combination of gonadotropin releasing hormone agonist and human chorionic gondadotropin significantly improves live birth rate for normal responders in GnRH antagonist cycles

Thursday, October 31, 2013
Dual trigger with gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin improves implantation, clinical pregnancy, and live-birth rates for normal responders in GnRH-antagonist IVF-ICSI cycles.

Read More

Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant FSH GnRH antagonist IVF cycles

Friday, August 30, 2013
In oocyte donors triggered with a bolus of GnRHa, gonadotropin and steroid levels during the early luteal phase differed significantly according to the type of luteal phase support used after triggering.

Read More

Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology

Friday, August 30, 2013
Endometrial hormone receptor expression was altered during ovarian stimulation cycles and was independent from serum E2 levels.

Read More

Early initiation of GnRH antagonist treatment results in a more stable endocrine milieu during the mid and late follicular phases an RCT comparing GnRH antagonist initiation…

Friday, August 30, 2013
Early initiation of GnRH antagonist cotreatment for IVF results in more stable levels of E2 and LH during the mid- and late-follicular phases.

Read More

Cost effectiveness comparison between pituitary down regulation with a gonadotropin releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments

Tuesday, April 30, 2013
Although the controlled ovarian stimulation protocol with short GnRH agonist in alternate days may lower the cost of an individual IVF cycle, it requires more cycles to achieve pregnancy.

Read More

Antimüllerian hormone in gonadotropin releasing hormone antagonist cycles Prediction of ovarian response and cumulative treatment outcome in good prognosis patients

Saturday, March 30, 2013
AMH predicts oocyte yield and poor and excessive ovarian response in GnRH antagonist cycles and is associated with increased cumulative live-birth rates after single-blastocyst transfer in fresh and cryopreserved cycles.

Read More

A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist

Monday, June 4, 2012
Treatment with gonadotropin-releasing hormone antagonist improved the clinical, laboratory and ultrasonographic parameters of a pituitary adenoma secreting follicle-stimulating hormone associated with ovarian hyperstimulation which persisted after transsphenoidal surgery.

Read More

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial

Wednesday, May 30, 2012
GnRH antagonist protocols allow friendly IVF procedures for patients but have low convenience to program oocyte retrievals. This study shows that estrogen pretreatment is effective and safe to program antagonist cycles.

Read More

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone

Wednesday, May 30, 2012
Live birth rates and cumulative pregnancy rates were higher in North America than in Europe after treatment with either corifollitropin alfa or daily recombinant FSH in a double-blind prospective randomized controlled trial.

Read More

Can we skip weekends in GnRH antagonist cycles without compromising the final outcome?

Wednesday, May 30, 2012
The author discusses the challenges in programming GnRH antagonist cycles.

Read More

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Wednesday, May 23, 2012
A randomized, assessor-blind, multicenter trial with compulsory single-blastocyst transfer documented that highly purified hMG is noninferior to rFSH regarding ongoing pregnancy in GnRH antagonist cycles.

Read More

Agonist trigger: what is the best approach? Agonist trigger and low dose hCG

Tuesday, May 22, 2012
Low-dose hCG supplementation after GnRHa trigger secures the reproductive outcome and minimizes the risk of OHSS in the high-risk IVF patient.

Read More

Agonist and antagonist coast

Tuesday, May 22, 2012
GnRH antagonist cycles are associated with a lower risk of OHSS and should be the protocol of choice in high-risk patients; and coasting is a useful protocol for prevention of OHSS.

Read More

Translate »